坦索罗辛预防女性盆腔重建术后尿潴留的随机对照试验
这项多中心双盲随机对照试验纳入119例盆腔器官脱垂手术女性,比较围术期10天坦索罗辛0.4mg与安慰剂。坦索罗辛组术后尿潴留发生率显著低于安慰剂组(8.8% vs 25.8%),尿路感染率无差异,两组AUA症状评分均改善。
要点
- 预防1例术后尿潴留需治疗5.9例患者。
- 两组尿路感染率无差异,坦索罗辛组尿流相关评分改善更明显(P=.03)。
核心结论
- 在盆腔器官脱垂手术女性中,围术期使用坦索罗辛与术后尿潴留风险降低相关。
研究设计与样本
- 多中心、双盲、随机对照试验,2018年8月至2020年6月纳入119例因盆腔器官脱垂手术的女性。
- 参与者随机接受10天围术期坦索罗辛0.4mg或安慰剂,术前3天开始。
- 术后第1天进行标准化排尿试验;排除术前残余尿量升高、术后尿潴留史、坦索罗辛禁忌及发生膀胱切开者。
主要发现
- 坦索罗辛组57例,安慰剂组62例,两组人口学、术前脱垂及排尿特征、手术细节相似。
- 预防1例术后尿潴留的需治疗人数为5.9例。
- 两组尿路感染率无差异;两组AUA症状指数总分术后均显著改善(中位数14 vs 7,P<.01)。
- 坦索罗辛组尿流相关评分改善优于安慰剂组(P=.03)。
关键数值与推荐
- 术后尿潴留定义为排尿试验失败或随后需导尿排空膀胱。
- 主要结局为术后尿潴留发生率;次要结局包括尿路感染率和AUA症状指数影响。
临床怎么用
- 对盆腔器官脱垂手术女性,可考虑围术期短期使用坦索罗辛0.4mg以降低术后尿潴留风险。
- 需权衡需治疗人数5.9例的获益与个体禁忌证。
局限性
- 发生膀胱切开者被排除分析,可能影响结果外推。
- 样本量119例,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative urinary retention is common after female pelvic reconstructive surgery. Alpha receptor antagonists can improve dysfunctional voiding by relaxing the bladder outlet and may be effective in reducing the risk of postoperative urinary retention. OBJECTIVE: This study aimed to determine whether tamsulosin is effective in preventing postoperative urinary retention in women undergoing surgery for pelvic organ prolapse. STUDY DESIGN: This was a multicenter, double-blind, randomized controlled trial between August 2018 and June 2020, including women undergoing surgery for pelvic organ prolapse. Patients were excluded from recruitment if they had elevated preoperative postvoid residual volume, history of postoperative urinary retention, or a contraindication to tamsulosin. Those who experienced cystotomy were excluded from analysis. Participants were randomized to a 10-day perioperative course of tamsulosin 0.4 mg vs placebo, beginning 3 days before surgery. A standardized voiding trial was performed on postoperative day 1. The primary outcome was the development of postoperative urinary retention, as defined by the failure of the voiding trial or subsequent need for catheterization to empty the bladder. Secondary outcomes included the rate of urinary tract infection and the impact on lower urinary tract symptoms as measured by the American Urological Association Symptom Index. RESULTS: Of 119 patients, 57 received tamsulosin and 62 received placebo. Groups were similar in regard to demographics, preoperative prolapse and voiding characteristics, and surgical details. Tamsulosin was associated with a lower rate of postoperative urinary retention than placebo (5 patients [8.8%] vs 16 patients [25.8%]; odds ratio, 0.28; 95% confidence interval, 0.09-81; P=.02). The number needed to treat to prevent 1 case of postoperative urinary retention was 5.9 patients. The rate of urinary tract infection did not differ between groups. American Urological Association Symptom Index scores significantly improved after surgery in both groups (median total score, 14 vs 7; P<.01). Scores related to urinary stream improved more in the tamsulosin group than in placebo (P=.03). CONCLUSION: In this placebo-controlled trial, tamsulosin use was associated with a reduced risk of postoperative urinary retention in women undergoing surgery for pelvic organ prolapse.
引用
- Chapman GC, Sheyn D, Slopnick EA, et al. Tamsulosin vs placebo to prevent postoperative urinary retention following female pelvic reconstructive surgery: a multicenter randomized controlled trial. Am J Obstet Gynecol. 2021. PMID: 33894146. doi:10.1016/j.ajog.2021.04.236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。